1. |
Hoffmann S, Burchert A, Wunderlich A, et al. Differential effects of cetuximab and AEE 788 on epidermal growth factor receptor (EGF-R) and vascular endothelial growth factor receptor (VEGF-R) in thyroid Cancer cell lines[J]. Endocrine, 2007, 31(2): 105-113.
|
2. |
Prichard CN, Kim S, Yazici YD, et al. Concurrent cetuximab and bevacizumab therapy in a murine orthotopic model of anaplastic thyroid carcinoma[J]. Laryngoscope, 2007, 117(4): 674-679.
|
3. |
Lothaire P, de Azambuja E, Dequanter D, et al. Molecular markers of head and neck squamous cell carcinoma: promising signs in need of prospective evaluation[J]. Head Neck, 2006, 28(3): 256-269.
|
4. |
O-charoenrat P, Rhys-Evans P, Modjtahedi H, et al. Vascular endothelial growth factor family members are differentially regulated by c-erbB signaling in head and neck squamous carcinoma cells[J]. Clin Exp Metastasis, 2000, 18(2): 155-161.
|
5. |
Vokes EE, Cohen EE, Mauer AM, et al. A phase I study of erlotinib and bevacizumab for recurrent or metastatic squamous cell carcinoma of the head and neck(HNC)[J]. J Clin Oncol, 2005, 23(16S): 5504.
|
6. |
Karamouzis M, Friedland D, Johnson R, et al. Phase II trial of pemetrexed(P)and bevacizumab(B)in patients(pts)with recurrent or metastatic head and neck squamous cell carcinoma(HNSCC):an interim analysis[J]. J Clin Oncol, 2007, 25(18S): 6049.
|
7. |
Gerber HP, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies[J]. Cancer Res, 2005, 65(3): 671-680.
|
8. |
Khan AJ, King BL, Smith BD, et al. Characterization of the HER-2/neu oncogene by immunohistochemical and fluorescence in situ hybridization analysis in oral and oropharyngeal squamous cell carcinoma[J]. Clin Cancer Res, 2002, 8(2): 540-548.
|
9. |
Gillison ML, Glisson BS, O’leary E, et al. Phase II trial of trastuzumab(T), paclitaxel(P)and cisplatin I in metastatic(M)or recurrent I head and neck squamous cell carcinoma(HNSCC): response by tumor EGFR and HER2/neu status[J]. J Clin Oncol, 2006, 24S(18Part 1): 282.
|
10. |
Widakowich C, de Castro G Jr, de Azambuja E, et al. Review: side effects of approved molecular targeted therapies in solid cancers[J]. Oncologist, 2007, 12(12): 1443-1455.
|
11. |
Lanzi C, Cassinelli G, Nicolini V, et al. Targeting RET for thyroid Cancer therapy[J]. Biochem Pharmacol, 2009, 77(3): 297-309.
|
12. |
Diaz-Cano SJ. Motesanib diphosphate in progressive differentiated thyroid Cancer[J]. N Engl J Med, 2008, 359(25): 2727.
|
13. |
Rusnak DW, Lackey K, Affleck K, et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo[J]. Mol Cancer Ther, 2001, 1(2): 85-94.
|
14. |
Abidoye OO, Cohen EE, Wong SJ, et al. A phase II study of lapatinib(GW572016)in recurrent/metastatic(R/M)squamous cell carcinoma of the head and neck(SCCHN)[J]. J Clin Oncol, 2006, 24(18S): 5568.
|
15. |
Bourhis J, Harrington K, Rosine D, et al. A phase I,open-label study(EGF100262)of lapatinib plus chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck(SCCHN)[J]. Ann Oncol, 2006, 17(Suppl 9): 180.
|
16. |
Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis[J]. Cancer Res, 2004, 64(19): 7099-7109.
|
17. |
Liu L, Cao Y, Chen C, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5[J]. Cancer Res, 2006, 66(24): 11851-11858.
|
18. |
Chang YS, Adnane J, Trail PA, et al. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models[J]. Cancer Chemother Pharmacol, 2007, 59(5): 561-574.
|
19. |
Williamson SK, Moon J, Huang CH, et al. in patients with recurrent and/or metastatic head and neck squamous cell carcinoma(HNSCC): a Southwest Oncology Group ( SWOG ) trial[C]//AY 43-9006, 2006.
|
20. |
Mandal M, Younes M, Swan EA, et al. The Akt inhibitor KP372-1 inhibits proliferation and induces apoptosis and anoikis in squamous cell carcinoma of the head and neck[J]. Oral Oncol, 2006, 42(4): 430-439.
|
21. |
Argiris A, Cohen E, Karrison T, et al. A phase II trial of perifosine,an oral alkylphospholipid, in recurrent or metastatic head and neck Cancer[J]. Cancer Biol Ther, 2006, 5(7): 766-770.
|
22. |
Janmaat ML, Kruyt FA, Rodriguez JA, et al. Response to epidermal growth factor receptor inhibitors in non-small cell lung Cancer cells:limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways[J]. Clin Cancer Res, 2003, 9(6): 2316-2326.
|
23. |
Schmelzle T, Hall MN. TOR, a central controller of cell growth[J]. Cell, 2000, 103(2): 253-262.
|
24. |
Aissat N, Le Tourneau C, Ghoul A, et al. Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck Cancer cell lines[J]. Cancer Chemother Pharmacol, 2008, 62(2): 305-313.
|
25. |
Amornphimoltham P, Patel V, Sodhi A, et al. Mammalian target of rapamycin,a molecular target in squamous cell carcinomas of the head and neck[J]. Cancer Res, 2005, 65(21): 9953-9961.
|
26. |
Siesser PM, Hanks SK. The signaling and biological implications of FAK overexpression in Cancer[J]. Clin Cancer Res, 2006, 12(11 Pt 1): 3233-3237.
|
27. |
Johnson FM, Saigal B, Talpaz M, et al. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung Cancer cells[J]. Clin Cancer Res, 2005, 11(19 Pt 1): 6924-6932.
|
28. |
Conticello C, Adamo L, Giuffrida R, et al. Proteasome inhibitors synergize with tumor necrosis factor-related apoptosis-induced ligand to induce anaplastic thyroid carcinoma cell death[J]. J Clin Endocrinol Metab, 2007, 92(5): 1938-1942.
|
29. |
Reiter R, Gais P, Jütting U, et al. Aurora kinase A messenger RNA overexpression is correlated with tumor progression and shortened survival in head and neck squamous cell carcinoma[J]. Clin Cancer Res, 2006, 12(17): 5136-5141.
|
30. |
Schellens JH, Boss D, Witteveen PO, et al. Phase I and pharmacological study of the novel Aurora kinase inhibitor AZD1152[J]. J Clin Oncol, 2006, 24S(18Part 1): 122.
|
31. |
Rubin EH, Shapiro GI, Stein MN, et al. A phase I clinical and pharmacokinetic(Pk)trial of the Aurora kinase(AK)inhibitor MK-0457 in Cancer patients[J]. J Clin Oncol, 2006, 24S(181): 123.
|
32. |
Patel V, Senderowicz AM, Pinto D Jr, et al. Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis[J]. J Clin Invest, 1998, 102(9): 1674-1681.
|
33. |
Marks PA, Rifkind RA, Richon VM, et al. Inhibitors of histone deacetylase are potentially effective anticancer agents[J]. Clin Cancer Res, 2001, 7(4): 759-760.
|
34. |
Zhang Y, Jung M, Dritschilo A, et al. Enhancement of radiation sensitivity of human squamous carcinoma cells by histone deacetylase inhibitors[J]. Radiat Res, 2004, 161(6): 667-674.
|